Clinical Trial Compliance Training Course

Participants can translate protocol requirements into practical compliance controls and accountability arrangements.

• Protocol synopsis reviewed for objectives, endpoints, population and study procedures
• Schedule of assessments converted into site-level operational compliance checkpoints
• Critical protocol procedures identified using critical-to-quality factor analysis
• Eligibility criteria assessed for ambiguity, feasibility and source evidence
• Protocol amendment impacts evaluated across consent, training and data collection
• Responsibility assignment matrix built for sponsor, CRO and investigator tasks

Participants can manage ethical approval and informed consent records in line with GCP expectations.

• Ethics committee submissions assembled with required protocol and participant documents
• Informed consent process assessed for timing, capacity and voluntary participation
• Consent form version control maintained through approval and implementation records
• Assent and legally authorised representative requirements applied to vulnerable participants
• Re-consent triggers identified following amendments, new risks and revised information
• Privacy notices aligned with consent, data processing and retention requirements

Participants can assess whether investigators and sites are prepared to conduct a compliant trial.

• Site feasibility criteria assessed against recruitment, facilities and competing studies
• Investigator qualifications documented through curriculum vitae, licences and training records
• Delegation of authority logs reviewed for task assignment and oversight
• Site initiation requirements verified before screening, enrolment and investigational product receipt
• Training matrices linked to protocol amendments, procedures and role changes
• Essential document deficiencies escalated using defined site activation criteria

Participants can establish compliant controls for investigational product receipt, storage and accountability.

• Investigational product chain of custody documented from depot to participant
• Temperature excursion assessment linked to storage specifications and product disposition
• Accountability logs reconciled against dispensing, returns and destruction records
• Blinding integrity protected through controlled randomisation and emergency unblinding processes
• Pharmacy delegation and training evidence verified before product handling
• Product complaints escalated through quality, safety and supply management channels

Participants can evaluate source documentation and electronic data controls for data integrity risks.

• ALCOA+ principles applied to paper, electronic and hybrid source records
• Source data verification distinguished from source data review objectives
• Electronic case report form entries traced to attributable source evidence
• Audit trails reviewed for contemporaneous changes, corrections and user accountability
• Data queries managed through documented resolution and investigator confirmation workflows
• Certified copies assessed for completeness, accuracy and retrieval capability

Participants can manage clinical trial safety reporting pathways and oversight responsibilities.

• Adverse events classified by seriousness, expectedness and causal relationship
• SAE reporting timelines mapped from site awareness to sponsor notification
• Suspected unexpected serious adverse reactions assessed under ICH E2A principles
• Safety reporting agreements reconciled between sponsor, CRO and investigational sites
• Annual safety reports supported by cumulative safety data and risk evaluation
• Pregnancy reports, overdoses and special situations managed through safety procedures

Participants can identify, classify, investigate and escalate protocol deviations and serious noncompliance.

• Deviation taxonomy distinguishes procedural errors, violations and serious noncompliance
• Impact assessment considers participant rights, safety and data credibility
• Immediate containment actions documented before formal deviation investigation begins
• Five Whys and fishbone analysis used for root-cause investigation
• Reportability decisions aligned with sponsor procedures and ethics requirements
• Trend analysis identifies recurrent deviations by site, procedure and cause

Participants can design CAPAs that resolve root causes and demonstrate sustained effectiveness.

• CAPA records connect issue statements, root causes and corrective actions
• Action plans specify owners, due dates, evidence and escalation thresholds
• Preventive actions address systemic risks beyond the individual observed event
• Effectiveness checks test whether CAPAs changed process performance sustainably
• Overdue CAPAs governed through quality review and management escalation
• CAPA closure decisions supported by objective evidence and residual-risk assessment

Participants can create a risk-based quality management approach for a clinical study.

• Quality tolerance limits defined for critical processes and study endpoints
• Risk assessment ranks probability, impact and detectability using FMEA
• Critical data and processes identified through protocol-driven risk analysis
• Key risk indicators designed with thresholds, trends and response actions
• Risk controls assigned to preventive, detective and corrective categories
• Quality management plan connects risks, controls, monitoring and governance

Participants can develop monitoring approaches proportionate to site, data and participant risks.

• Monitoring plan defines centralised, remote and on-site monitoring activities
• Site risk profiles combine enrolment, deviations, data trends and safety signals
• Targeted source data review focuses on critical data and processes
• Monitoring visit reports distinguish observations, actions and escalation decisions
• Follow-up letters document agreed actions, owners and completion evidence
• Central monitoring signals trigger focused review or site intervention

Participants can assess trial master file completeness, quality and inspection readiness.

• TMF reference model used to structure essential document filing
• Document metadata checked for version, date, owner and approval status
• Timeliness metrics identify late filing and potential contemporaneousness concerns
• TMF quality control checks completeness, legibility, consistency and retrievability
• Electronic TMF access controls governed through roles, audit trails and backups
• Archiving plans define retention periods, transfer responsibilities and retrieval procedures

Participants can establish evidence-based oversight of outsourced clinical trial activities.

• Vendor qualification assesses capability, quality systems and regulatory inspection history
• Service agreements define responsibilities, deliverables, reporting and escalation pathways
• Oversight plans set governance meetings, metrics and issue-management routines
• Quality agreements allocate deviation, CAPA and audit notification responsibilities
• Vendor performance metrics reviewed against service levels and quality thresholds
• Transfer of obligations assessed when subcontractors perform regulated trial activities

Participants can prepare teams, evidence and responses for audits and regulatory inspections.

• Audit plans prioritise high-risk processes, sites and outsourced activities
• Audit evidence collected through interviews, records review and process tracing
• Inspection readiness rooms organise documents, subject matter experts and response logs
• Inspector questions answered with factual evidence, ownership and controlled escalation
• Audit findings classified by severity, systemic impact and regulatory significance
• Response commitments tracked through CAPA governance and effectiveness verification

Participants can assess compliance controls for systems used to create and manage trial records.

• Computerised system validation linked to intended use and patient safety
• User access reviews verify least privilege and timely account removal
• Electronic signatures assessed for attribution, authentication and record linkage
• Change control evaluates validated-state impacts before system configuration changes
• Data migration evidence confirms completeness, accuracy and reconciliation outcomes
• Supplier audits assess hosted platform controls and business continuity arrangements

Participants can plan compliant trial registration and results disclosure activities.

• Registration responsibilities assigned before first participant enrolment begins
• ClinicalTrials.gov records maintained for protocol changes and recruitment status
• EU clinical trial information submissions aligned with transparency requirements
• Results disclosure timelines monitored through ownership and governance controls
• Public registry data reconciled with protocol, statistical plan and final reports
• Disclosure risks assessed for inaccurate records, late submissions and missing results

Participants can manage compliance activities required at study close-out and after completion.

• Close-out visits confirm investigational product reconciliation and document completion
• Outstanding data queries, deviations and CAPAs tracked to documented closure
• Site close-out letters record retention obligations and post-study contacts
• Clinical study report evidence traced to approved analyses and source records
• Archival inventories verify essential documents, media formats and retrieval arrangements
• Post-study lessons learned translated into procedural and training improvements

Participants can design governance routines that sustain accountable clinical trial compliance.

• Quality governance forums review risks, metrics, deviations and CAPA status
• Escalation pathways define decision rights for urgent participant safety issues
• Management review uses trend data to direct quality improvement resources
• Compliance dashboards combine quality tolerance limits, KRIs and action status
• Training effectiveness measured through performance evidence and recurring error trends
• Speak-up mechanisms support early reporting of ethical and compliance concerns

Participants can build, review and present a complete inspection-ready compliance package for a multicentre clinical trial.

• Study scenario analysed for participant safety, data integrity and oversight risks
• Protocol compliance plan drafted with accountable owners and critical controls
• Risk assessment converted into quality tolerance limits and monitoring priorities
• Deviation investigation and CAPA package completed from documented trial evidence
• TMF readiness review identifies missing, late and inconsistent essential documents
• Inspection response briefing presents evidence, residual risks and remediation commitments